Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era

Blood

Volumn 123, Issue 23, 2014, Pages 3553-3562

  Tao, Li ^a   Foran, James M ^b   Clarke, Christina A ^a,c   Gomez, Scarlett L ^a,c   Keegan, Theresa H M ^a,c  

^a CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; HUMAN; INFANT; INSURANCE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MARRIED PERSON; MIDDLE AGED; PRIORITY JOURNAL; RACE DIFFERENCE; SOCIAL STATUS; SOCIOECONOMICS; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALIFORNIA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HEALTH STATUS DISPARITIES; HUMANS; INFANT; INFANT, NEWBORN; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; SOCIAL CLASS; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 84902140888     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-07-517110     Document Type: Article

References (67)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998;16(8):2780-2795. (Pubitemid 28363044)
2. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997; 89(11):3909-3918.
3. Fisher RI, Miller TP, O'Connor OA. Diffuse aggressive lymphoma. Hematology (Am Soc Hematol Educ Program). 2004;221-236.
4. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328(14):1002-1006. (Pubitemid 23095683)
5. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987-994.
6. Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5): 1857-1861. (Pubitemid 46348180)
7. Komrokji RS, Al Ali NH, Beg MS, et al. Outcome of diffuse large B-cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data. Clin Lymphoma Myeloma Leuk. 2011;11(3):257-260.
8. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4): 235-242. (Pubitemid 34438862)
9. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute at the National Institutes of Health; based on November 2011 SEER data submission, posted April 2012. SEER Web site. http://seer.cancer.gov/csr/1975-2009-pops09/. Accessed September 12, 2012.
10. Division of Cancer Control and Population Sciences (DCCPS), Surveillance Research Program, Surveillance Systems Branch. SEER*Stat Databases: November 2011 Submission. Survival, Case Listing, and Frequency Sessions. Incidence - SEER 18 Regs Research Data 1 Hurricane Katrina Impacted Louisiana Cases, Nov 2011 Sub (1973-2009 varying). Linked To County Attributes Total U.S., 1969-2010 Counties. Bethesda, MD: National Cancer Institute at the National Institutes of Health; released April 2012. SEER Web site. http://seer.cancer. gov/data/seerstat/nov2011/.Accessed September 12, 2012.
11. Griffiths R, Gleeson M, Knopf K, Danese M. Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL). BMC Cancer. 2010;10:625.
12. Shenoy PJ, Malik N, Nooka A, et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer. 2011;117(11):2530-2540.
13. Flowers CR, Shenoy PJ, Borate U, et al. Examining racial differences in diffuse large B-cell lymphoma presentation and survival. Leuk Lymphoma. 2013;54(2):268-276.
14. Wang M, Burau KD, Fang S, Wang H, Du XL. Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large population-based cohort of elderly patients with non-Hodgkin lymphoma. Cancer. 2008;113(11): 3231-3241.
15. Byers TE, Wolf HJ, Bauer KR, et al; Patterns of Care Study Group. The impact of socioeconomic status on survival after cancer in the United States: findings from the National Program of Cancer Registries Patterns of Care Study. Cancer. 2008;113(3):582-591.
16. Cella DF, Orav EJ, Kornblith AB, et al. Socioeconomic status and cancer survival. J Clin Oncol. 1991;9(8):1500-1509.
17. Kogevinas M, Porta M. Socioeconomic differences in cancer survival: a review of the evidence. IARC Sci Publ. 1997;(138):177-206.
18. Keegan TH, McClure LA, Foran JM, Clarke CA. Improvements in survival after follicular lymphoma by race/ethnicity and socioeconomic status: a population-based study. J Clin Oncol. 2009; 27(18):3044-3051.
19. Woods LM, Rachet B, Coleman MP. Origins of socio-economic inequalities in cancer survival: a review. Ann Oncol. 2006;17(1):5-19. (Pubitemid 43033834)
20. Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110(2):695-708. (Pubitemid 47105409)
21. North American Association of Central Cancer Registries NAACCR ICD-O-3 Implementation Work Group. Guidelines for ICD-O-3 implementation. North American Association of Central Cancer Registries Web site. http://www.naaccr.org. Accessed June 10, 2012.
22. World Health Organization. International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3). Geneva, Switzerland: WHO; 2000.
23. Smith EC, Ziogas A, Anton-Culver H. Association between insurance and socioeconomic status and risk of advanced stage Hodgkin lymphoma in adolescents and young adults. Cancer. 2012; 118(24):6179-6187.
24. Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control. 2001;12(8): 703-711. (Pubitemid 32803497)
25. Reynolds P, Hurley SE, Quach AT, et al. Regional variations in breast cancer incidence among California women, 1988-1997. Cancer Causes Control. 2005;16(2):139-150. (Pubitemid 40685057)
26. Urayama KY, Von Behren J, Reynolds P, Hertz A, Does M, Buffler PA. Factors associated with residential mobility in children with leukemia: implications for assigning exposures. Ann Epidemiol. 2009;19(11):834-840.
27. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16(8):2825-2833. (Pubitemid 28363048)
28. Scott SD. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. Cancer Pract. 1998;6(3):195-197. (Pubitemid 28225643)
29. Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene. 2007;26(25):3603-3613. (Pubitemid 46844778)
30. Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med. 2008;59:237-250. (Pubitemid 351291630)
31. Coiffier B, Gisselbrecht C, Bosly A, et al. 10 years follow-up of the GELA LNH98.5 study, first randomized study comparing R-CHOP to CHOP chemotherapy in patients with diffuse large B-cell lymphoma [abstract]. Blood. 2009;114(22). Abstract 3741.
32. Kent EE, Morris RA, Largent JA, Ziogas A, Sender LS, Anton-Culver H. Socioeconomic impacts on survival differ by race/ethnicity among adolescents and young adults with non-Hodgkin's lymphoma. J Cancer Epidemiol. 2010;2010: 824691.
33. Varterasian ML, Graff JJ, Severson RK, Weiss L, al-Katib AM, Kalemkerian GP. Non-Hodgkin's lymphoma: an analysis of the Metropolitan Detroit SEER database. Cancer Invest. 2000;18(4): 303-308. (Pubitemid 30210961)
34. Aizer AA, Chen MH, McCarthy EP, et al. Marital status and survival in patients with cancer. J Clin Oncol. 2013;31(31):3869-3876.
35. Cronin-Fenton DP, Sharp L, Deady S, Comber H. Treatment and survival for non-Hodgkin's lymphoma: influence of histological subtype, age, and other factors in a population-based study (1999-2001). Eur J Cancer. 2006;42(16): 2786-2793. (Pubitemid 44584661)
36. Johnson NJ, Backlund E, Sorlie PD, Loveless CA. Marital status and mortality: the national longitudinal mortality study. Ann Epidemiol. 2000; 10(4):224-238. (Pubitemid 30330956)
37. Cohen SD, Sharma T, Acquaviva K, Peterson RA, Patel SS, Kimmel PL. Social support and chronic kidney disease: an update. Adv Chronic Kidney Dis. 2007;14(4):335-344. (Pubitemid 47451830)
38. Goldzweig G, Andritsch E, Hubert A, et al. Psychological distress among male patients and male spouses: what do oncologists need to know? Ann Oncol. 2010;21(4):877-883.
39. Auvinen A, Karjalainen S, Pukkala E. Social class and cancer patient survival in Finland. Am J Epidemiol. 1995;142(10):1089-1102.
40. Singh GK, Miller BA, Hankey BF, Edwards BK. Area Socioeconomic Variations in US Cancer Incidence, Mortality, Stage, Treatment, and Survival, 1975-1999. Bethesda, MD: National Cancer Institute; 2003.
41. Auvinen A, Karjalainen S. Possible explanations for social class differences in cancer patient survival. IARC Sci Publ. 1997;(138):377-397.
42. Bradley CJ, Given CW, Roberts C. Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst. 2002; 94(7):490-496. (Pubitemid 34411287)
43. Mandelblatt JS, Yabroff KR, Kerner JF. Equitable access to cancer services: a review of barriers to quality care. Cancer. 1999;86(11):2378-2390. (Pubitemid 30010381)
44. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002;287(16): 2106-2113. (Pubitemid 34437345)
45. Ward E, Halpern M, Schrag N, et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin. 2008;58(1):9-31.
46. Cohen RA, Ward BW, Schiller JS. Health insurance coverage: early release of estimates from the National Health Interview Survey, 2010. National Center for Health Statistics. June 2011. CDC Web site. http://www.cdc.gov/nchs/nhis. htm. Accessed August 10, 2012.
47. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993;31(8): 732-748.
48. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(suppl 8):IV-3-IV-18.
49. Pollack CE, Armstrong K. Accountable care organizations and health care disparities. JAMA. 2011;305(16):1706-1707.
50. Ferrara F, Ravasio R. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma. Clin Drug Investig. 2008;28(1):55-65. (Pubitemid 350274401)
51. Johnston KM, Marra CA, Connors JM, Najafzadeh M, Sehn L, Peacock SJ. Costeffectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada. Value Health. 2010;13(6):703-711.
52. Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large Bcell lymphoma. Cancer. 2005;103(8):1644-1651. (Pubitemid 40490025)
53. Griffiths RI, Gleeson ML, Mikhael J, Dreyling MH, Danese MD. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma. Cancer. 2012;118(24):6079-6088.
54. Adler NE, Boyce T, Chesney MA, et al. Socioeconomic status and health. The challenge of the gradient. Am Psychol. 1994;49(1):15-24. (Pubitemid 24976661)
55. Wagner EH. Meeting the needs of chronically ill people. BMJ. 2001;323(7319):945-946. (Pubitemid 33016037)
56. White K, Haas JS, Williams DR. Elucidating the role of place in health care disparities: the example of racial/ethnic residential segregation. Health Serv Res. 2012;47(3 Pt 2):1278-1299.
57. Feugier P, Van Hoof A, Sebban C, et al. Longterm results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005; 23(18):4117-4126. (Pubitemid 46211317)
58. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24(19):3121-3127. (Pubitemid 46638950)
59. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027-5033. (Pubitemid 46224009)
60. Clarke CA, Glaser SL, Dorfman RF, Bracci PM, Eberle E, Holly EA. Expert review of non- Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications. Cancer Epidemiol Biomarkers Prev. 2004;13(1):138-143. (Pubitemid 38116631)
61. Clarke CA, Undurraga DM, Harasty PJ, Glaser SL, Morton LM, Holly EA. Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev. 2006; 15(4):630-638.
62. Rosenwald A, Wright G, Chan WC, et al; Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25): 1937-1947. (Pubitemid 34651353)
63. Krieger N. Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. Am J Public Health. 1992;82(5): 703-710.
64. Pickett KE, Pearl M. Multilevel analyses of neighbourhood socioeconomic context and health outcomes: a critical review. J Epidemiol Community Health. 2001;55(2):111-122. (Pubitemid 32095197)
65. Robert SA. Community-level socioeconomic status effects on adult health. J Health Soc Behav. 1998;39(1):18-37. (Pubitemid 128453810)
66. Keegan TH, Glaser SL, Clarke CA, et al. Epstein- Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. J Clin Oncol. 2005;23(30):7604-7613. (Pubitemid 46291824)
67. Sehn LH. Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2012;2012:402-409.